Alpha 2.0
Login Register
» Articles » PMID: 26176392

Oral Propranolol for Infantile Hemangioma

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2015 Jul 16
PMID 26176392
Citations 6
Authors
Christine Leaute-Labreze
Jean-Jacques Voisard
Nicholas Moore
Affiliations
Soon will be listed here.
Citing Articles

Our Experience in Treating Infantile Hemangioma: Prognostic Factors for Relapse After Propranolol Discontinuation.

Zaaroura H, Tibi A, Avitan-Hersh E, Khamaysi Z Adv Ther. 2024; 42(1):537-547.

PMID: 39589452 PMC: 11782296. DOI: 10.1007/s12325-024-03017-2.

PHACE Syndrome in a Child with Structural Malformations of the Brain.

Aygunes U, Dogan M, Keceli A J Pediatr Genet. 2021; 10(4):315-318.

PMID: 34849278 PMC: 8608460. DOI: 10.1055/s-0040-1714066.

R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma.

Overman J, Fontaine F, Wylie-Sears J, Moustaqil M, Huang L, Meurer M Elife. 2019; 8.

PMID: 31358114 PMC: 6667216. DOI: 10.7554/eLife.43026.

Oral Propranolol in Infantile Hemangiomas: Analysis of Factors that Affect the Outcome.

Ainipully A, Narayanan S, Vazhiyodan A, Somnath P J Indian Assoc Pediatr Surg. 2019; 24(3):170-175.

PMID: 31258264 PMC: 6568152. DOI: 10.4103/jiaps.JIAPS_12_18.

Propranolol therapy for infantile hemangioma: our experience.

Zhang L, Wu H, Yuan W, Zheng J Drug Des Devel Ther. 2017; 11:1401-1408.

PMID: 28507428 PMC: 5428756. DOI: 10.2147/DDDT.S134808.